loaderimg
image

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.

Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Company’s Keywords:

Q How Many Employees Does This Company Have?

<36

Q Which Industry Does This Company Belong To?

Q What Is the Annual Income?

<

Q What Is the Technology of All the Company’s Website?

Q What Year Was the Company Founded?

<2016

Rate us and Write a Review

Your review is recommended to be at least 140 characters long

image

building Own or work here? Claim Now! Claim Now!

imageYour request has been submitted successfully.

image